This 2024 retrospective cohort study analyzed data from over 600,000 men to assess whether the use of glycolysis-enhancing α1-adrenergic receptor antagonists—terazosin, doxazosin, or alfuzosin (Tz/Dz/Az)—is associated with a reduced risk of developing dementia with Lewy bodies (DLB). Compared to men taking tamsulosin or 5α-reductase inhibitors (5ARIs), those on Tz/Dz/Az had
